Stephen R. Bloom
YOU?
Author Swipe
View article: SUN-685 A comparison of the metabolic effects of a long-acting GIPR agonist versus a GIPR antagonist
SUN-685 A comparison of the metabolic effects of a long-acting GIPR agonist versus a GIPR antagonist Open
Disclosure: I. Davies: None. A. Turland: None. C. Wong: None. H. Tran: None. O. Cahn: None. S.R. Bloom: Zihipp. B. Jones: Metsera, Eli Lilly and Company, Sun Pharma. T. Tan: Zihipp. Introduction: There is significant interest in targeting …
View article: Seasonal changes in physical oceanography modulate cetacean predator-prey dynamics in the San Diego Trough
Seasonal changes in physical oceanography modulate cetacean predator-prey dynamics in the San Diego Trough Open
In marine ecosystems, cetaceans are large mobile predators that depend on maximizing foraging efficiency. Their presence within a habitat can therefore be strongly related to the modulation of local prey by oceanographic conditions. Unders…
View article: The physiological impact of an N‐terminal Halo‐tag on glucose‐dependent insulinotropic polypeptide receptor function in mice
The physiological impact of an N‐terminal Halo‐tag on glucose‐dependent insulinotropic polypeptide receptor function in mice Open
View article: Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation
Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation Open
View article: 60-month follow-up of Long Limb vs. Standard Limb Roux-en-Y gastric bypass for type 2 diabetes and obesity: the LONG LIMB RCT
60-month follow-up of Long Limb vs. Standard Limb Roux-en-Y gastric bypass for type 2 diabetes and obesity: the LONG LIMB RCT Open
Background Roux-en-Y gastric bypass is an established treatment option for type 2 diabetes and obesity. However, the optimal lengths for the small intestinal limbs remain controversial with variation in practice. A longer biliopancreatic l…
View article: Fasting pancreatic polypeptide predicts incident microvascular and macrovascular complications of type 2 diabetes: An observational study
Fasting pancreatic polypeptide predicts incident microvascular and macrovascular complications of type 2 diabetes: An observational study Open
Aims Pancreatic polypeptide (PP) is elevated in people with vascular risk factors such as type 2 diabetes or increased visceral fat. We investigated potential relationships between PP and microvascular and macrovascular complications of di…
View article: Intra-islet glucagon signalling regulates beta-cell connectivity, first-phase insulin secretion and glucose homoeostasis
Intra-islet glucagon signalling regulates beta-cell connectivity, first-phase insulin secretion and glucose homoeostasis Open
View article: The vagus nerve mediates the physiological but not pharmacological effects of PYY3-36 on food intake
The vagus nerve mediates the physiological but not pharmacological effects of PYY3-36 on food intake Open
View article: Adaptive infusion of a glucagon‐like peptide‐1/glucagon receptor co‐agonist <scp>G3215</scp> , in adults with overweight or obesity: Results from a phase 1 randomized clinical trial
Adaptive infusion of a glucagon‐like peptide‐1/glucagon receptor co‐agonist <span>G3215</span> , in adults with overweight or obesity: Results from a phase 1 randomized clinical trial Open
Aims To determine whether a continuous infusion of a glucagon‐like peptide receptor (GLP‐1R)/glucagon receptor (GCGR) co‐agonist, G3215 is safe and well tolerated in adults with overweight or obesity. Methods A phase 1 randomized, double b…
View article: Abolishing β‐arrestin recruitment is necessary for the full metabolic benefits of G protein‐biased glucagon‐like peptide‐1 receptor agonists
Abolishing β‐arrestin recruitment is necessary for the full metabolic benefits of G protein‐biased glucagon‐like peptide‐1 receptor agonists Open
Aim Earlier studies have shown that peptide glucagon‐like peptide‐1 receptor (GLP‐1R) agonists with reduced β‐arrestin recruitment show enhanced anti‐hyperglycaemic efficacy through avoidance of GLP‐1R desensitization. However, the ligand …
View article: OR34-02 Fasting Pancreatic Polypeptide Predicts Incident Microvascular And Macrovascular Complications Of Type 2 Diabetes
OR34-02 Fasting Pancreatic Polypeptide Predicts Incident Microvascular And Macrovascular Complications Of Type 2 Diabetes Open
Disclosure: A.H. Sam: None. A.J. Buckley: None. B.Y. Lam: None. P.R. Bech: None. K. Meeran: None. M.T. Barakat: None. S.R. Bloom: None. G.S. Yeo: None. N.G. Lessan: None. K.G. Murphy: None. Background: Pancreatic polypeptide (PP) is elevat…
View article: EMBIO trial study protocol: left gastric artery embolisation for weight loss in patients living with obesity with a BMI 35–50 kg/m <sup>2</sup>
EMBIO trial study protocol: left gastric artery embolisation for weight loss in patients living with obesity with a BMI 35–50 kg/m <sup>2</sup> Open
Introduction Left gastric artery embolisation (LGAE) is a well-established treatment for major upper gastrointestinal (GI) bleeding when control is not established via upper GI endoscopy and recently has shown promising results for weight …
View article: Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry
Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry Open
View article: Comparison of an Initial Risk-Based Testing Strategy vs Usual Testing in Stable Symptomatic Patients With Suspected Coronary Artery Disease
Comparison of an Initial Risk-Based Testing Strategy vs Usual Testing in Stable Symptomatic Patients With Suspected Coronary Artery Disease Open
Importance Trials showing equivalent or better outcomes with initial evaluation using coronary computed tomography angiography (cCTA) compared with stress testing in patients with stable chest pain have informed guidelines but raise questi…
View article: Deferred Testing in Stable Outpatients With Suspected Coronary Artery Disease
Deferred Testing in Stable Outpatients With Suspected Coronary Artery Disease Open
Importance Guidelines recommend deferral of testing for symptomatic people with suspected coronary artery disease (CAD) and low pretest probability. To our knowledge, no randomized trial has prospectively evaluated such a strategy. Objecti…
View article: Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry
Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry Open
View article: 第41回内分泌代謝学サマーセミナープログラム・講演要旨集
第41回内分泌代謝学サマーセミナープログラム・講演要旨集 Open
View article: 100 years of glucagon and 100 more
100 years of glucagon and 100 more Open
View article: Sleeve gastrectomy causes weight‐loss independent improvements in hepatic steatosis
Sleeve gastrectomy causes weight‐loss independent improvements in hepatic steatosis Open
Background and Aims Sleeve gastrectomy (VSG) leads to improvement in hepatic steatosis, associated with weight loss. The aims of this study were to investigate whether VSG leads to weight‐loss independent improvements in liver steatosis in…
View article: Neuromedin U receptors in GtoPdb v.2023.1
Neuromedin U receptors in GtoPdb v.2023.1 Open
Neuromedin U receptors (provisional nomenclature as recommended by NC-IUPHAR [30]) are activated by the endogenous 25 amino acid peptide neuromedin U (neuromedin U-25, NmU-25), a peptide originally isolated from pig spinal cord [92]. In hu…
View article: Commentary on “The road to reliable peptide assays is paved with good guidelines”
Commentary on “The road to reliable peptide assays is paved with good guidelines” Open
We note that Maurer et al., in their correspondence,1 have raised some concerns about the preanalytical and analytical validation of the peptide YY (PYY) assay described in our paper ‘The postprandial secretion of peptide YY1–36 and 3–36 i…
View article: Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes/diabetes but promotes restraint eating: A secondary analysis of a randomized single‐blind placebo‐controlled study
Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes/diabetes but promotes restraint eating: A secondary analysis of a randomized single‐blind placebo‐controlled study Open
Aims To investigate whether the elevation in postprandial concentrations of the gut hormones glucagon‐like peptide‐1 (GLP‐1), oxyntomodulin (OXM) and peptide YY (PYY) accounts for the beneficial changes in food preferences, sweet taste fun…
View article: Fasting Pancreatic Polypeptide Predicts Incident Microvascular and Macrovascular Complications of Type 2 Diabetes: An Observational Study
Fasting Pancreatic Polypeptide Predicts Incident Microvascular and Macrovascular Complications of Type 2 Diabetes: An Observational Study Open
View article: The postprandial secretion of peptide YY<sub>1‐36</sub> and <sub>3‐36</sub> in obesity is differentially increased after gastric bypass versus sleeve gastrectomy
The postprandial secretion of peptide YY<sub>1‐36</sub> and <sub>3‐36</sub> in obesity is differentially increased after gastric bypass versus sleeve gastrectomy Open
Objectives Peptide tyrosine tyrosine (PYY) exists as two species, PYY 1‐36 and PYY 3‐36 , with distinct effects on insulin secretion and appetite regulation. The detailed effects of bariatric surgery on PYY 1‐36 and PYY 3‐36 secretion are …
View article: Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss
Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss Open
View article: Hepatocyte cholesterol content modulates glucagon receptor signalling
Hepatocyte cholesterol content modulates glucagon receptor signalling Open
Our results indicate that cellular cholesterol content influences glucagon sensitivity and indicate a potential molecular basis for this phenomenon. This could be relevant to the pathogenesis of non-alcoholic fatty liver disease, which is …
View article: Hepatocyte cholesterol content modulates glucagon receptor signalling
Hepatocyte cholesterol content modulates glucagon receptor signalling Open
Summary Glucagon decreases liver fat, and non-alcoholic fatty liver disease (NAFLD) is associated with hepatic glucagon resistance. Increasingly it is recognised that the function of G protein-coupled receptors can be regulated by their lo…
View article: The Metabolomic Effects of Tripeptide Gut Hormone Infusion Compared to Roux-en-Y Gastric Bypass and Caloric Restriction
The Metabolomic Effects of Tripeptide Gut Hormone Infusion Compared to Roux-en-Y Gastric Bypass and Caloric Restriction Open
Context The gut-derived peptide hormones glucagon-like peptide-1 (GLP-1), oxyntomodulin (OXM), and peptide YY (PYY) are regulators of energy intake and glucose homeostasis and are thought to contribute to the glucose-lowering effects of ba…
View article: Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking
Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking Open
The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor and mainstay therapeutic target for the treatment of type 2 diabetes and obesity. Recent reports have highlighted how biased agonism at the GLP-1R affect…
View article: Receptor Activity-Modifying Protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signalling
Receptor Activity-Modifying Protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signalling Open
By retaining GCGR intracellularly, RAMP2 alters the spatiotemporal pattern of GCGR signalling. Further exploration of the effects of RAMP2 on GCGR in vivo is warranted.